Gilead's Trodelvy New Subgroup Data Shows Benefit in Second-Line Breast Cancer Patients

  • Gilead Sciences Inc GILD has announced new data from the Phase 3 ASCENT study evaluating Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC).
  • Data were presented at the American Society of Clinical Oncology Annual Meeting.
  • Trodelvy extended survival in a subgroup analysis of relapsed or refractory triple-negative breast cancer patients in the second line.
  • In second-line patients who reported disease progression within 12 months of (neo)adjuvant chemo, Trodelvy cut the risk of disease worsening or death by 59% over chemo.
  • In this sub-group, progression-free survival of 5.7 months compared with 1.5 months on chemo was reported.
  • The therapy also posted a median overall survival of 10.9 months compared with 4.9 months for patients on chemo.
  • Trodelvy also showed a higher overall response rate compared with chemo (30% vs. 3 %).
  • No treatment-related deaths in the subgroup were reported.
  • Price Action: GILD shares are up 1.29% at $67.34 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralbreast cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!